Medical device manufacturer Applied Neurodiagnostics (ANL) has secured £1.2 million in a funding package supplied by North Star Equity Investors, British angel investors and US-based Applied Science Group.
Medical device manufacturer Applied Neurodiagnostics (ANL) has secured £1.2 million in a funding package supplied by North Star Equity Investors, British angel investors and US-based Applied Science Group.
North Star Equity Investors’ co-investment fund supplied £590,000 as part of the deal.
ANL aims to use the funding to manufacture eye-tracking products, which monitor the movement of the eye and can diagnose early-stage neurological disorders.
The investment will enable its devices to undergo clinical trials and commercialisation. ANL is also looking to expand in the UK and develop new products.
Based in Cramlington, Northumberland, the company is already manufacturing eye-tracking devices for the US medical market.
